Search | Clinical Trials Finder

Conditions: Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
Interventions: extracorporeal photopheresis; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Positron Emission Tomography, Tazemetostat; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Lymphoma
Interventions: filgrastim, carboplatin, carmustine, cyclophosphamide, cytarabine, etoposide, ifosfamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 120 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine, Pomalidomide; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Atlanta, Georgia • Kansas City, Kansas • Westwood, Kansas + 8 more

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Ponatinib, Prednisone, Rituximab, Vincristine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography; Drug · Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, FDG-Positron Emission Tomography, Pomalidomide, Teclistamab; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: trastuzumab, carboplatin, cyclophosphamide, melphalan, thiotepa, adjuvant therapy, autologous-autologous tandem hematopoietic stem cell transplantation, bone marrow ablation with stem cell support, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
Interventions: Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pretargeted Radioimmunotherapy, Total-Body Irradiation, Biospecimen Collection, Single Photon Emission Computed Tomography; Drug · Procedure · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
Interventions: Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Associated Lymphoma
Interventions: HST-NEETs, Bone Marrow Transplant; Biological
Lead sponsor: Catherine Bollard; NIH
Eligibility: 15 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 11
States / cities: Duarte, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Multigated Acquisition Scan, Positron Emission Tomography, Transplant Conditioning, X-Ray Imaging; Procedure · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cancer
Interventions: Cancer Treatment Options; Other
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: Not listed
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Neuroblastoma, Cancer
Interventions: Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib; Procedure · Genetic · Other + 2 more
Lead sponsor: Yael P Mosse; Other
Eligibility: 1 Year to 21 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: Naresh Bumma; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hematologic Diseases
Interventions: Not listed
Lead sponsor: Invivoscribe, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Osteoarthritis, Knee
Interventions: BMA cell therapy injection; Procedure
Lead sponsor: Advanced Orthopaedic Specialists; Other
Eligibility: 18 Years to 79 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Echocardiography Test, miR-126 Inhibitor miRisten; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Peripheral T Cell Lymphoma
Interventions: Tumor biopsy, Peripheral blood draw, Lymphotrack TCR clonality assay; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York

Conditions: Non-Hodgkin's Lymphoma
Interventions: Procurement of Follicular B Cell Lymphoma Cells; Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 35 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Rituximab, Venetoclax; Procedure · Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Idopathic Inflammatory/Autoimmune Syndromes
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Hydroxyurea, Luspatercept, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib, Dexamethasone, Dexamethasone Sodium Phosphate, Echocardiography, Lenalidomide, Navtemadlin; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 7
States / cities: Sacramento, California • Aurora, Colorado • New York, New York + 4 more

Conditions: Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Months to 21 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 186
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more

Search by objective public record fields.

Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

Genome Sequencing of Human Cancer Tissues

Next Generation Personalized Neuroblastoma Therapy

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research

Open Ended Trocar vs. Fenestrated Blunt Trocar in Bone Marrow Aspirate for Osteoarthritis

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Minimal Residual Disease in Peripheral T-cell Lymphoma

Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials

Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Collection of Blood, Bone Marrow, Leukapheresis, and Tissue Biopsy Samples From Patients and Their Family Members for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases Laboratory Research Studies

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations